Publicacions en col·laboració amb investigadors/es de Hospital Morales Meseguer (53)

2024

  1. Dynamic assessment of CHA2DS2-VASc and HAS-BLED scores for predicting ischemic stroke and major bleeding in atrial fibrillation patients

    Revista Espanola de Cardiologia, Vol. 77, Núm. 10, pp. 835-842

2023

  1. Adverse Clinical Outcomes and Associated Predictors in Rivaroxaban-Treated Atrial Fibrillation Patients With Renal Impairment

    American Journal of Cardiology, Vol. 203, pp. 122-127

  2. Imaging in atrial fibrillation: A way to assess atrial fibrosis and remodeling to assist decision-making

    American Heart Journal, Vol. 258, pp. 1-16

  3. Impact of particulate matter on the incidence of atrial fibrillation and the risk of adverse clinical outcomes: A review

    Science of the Total Environment, Vol. 880

  4. Polypharmacy and adverse events in atrial fibrillation: Main cause or reflection of multimorbidity?

    Biomedicine and Pharmacotherapy, Vol. 158

  5. Reducing bleeding risk in patients on oral anticoagulation therapy

    Expert Review of Cardiovascular Therapy, Vol. 21, Núm. 12, pp. 923-936

  6. The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort

    Journal of General Internal Medicine, Vol. 38, Núm. 2, pp. 315-323

2022

  1. Editorial: New horizons in the management of patients with atrial fibrillation: Interactions with the gastrointestinal system

    Frontiers in Cardiovascular Medicine

  2. Number needed to treat for net effect of anticoagulation in atrial fibrillation: Real-world vs. clinical-trial evidence

    British Journal of Clinical Pharmacology, Vol. 88, Núm. 1, pp. 282-289

  3. Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry

    European heart journal. Cardiovascular pharmacotherapy, Vol. 9, Núm. 1, pp. 38-46

  4. Prediction of ischemic stroke in different populations: a comparison of absolute stroke risk and CHA2DS2-VASc in real-world and clinical trial patients

    European Journal of Internal Medicine

  5. Relation of the ‘Atrial Fibrillation Better Care (ABC) Pathway’ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists

    Journal of Personalized Medicine, Vol. 12, Núm. 3

  6. Relationship between temporal rhythm-based classification of atrial fibrillation and stroke: real-world vs. clinical trial

    Journal of Thrombosis and Thrombolysis, Vol. 54, Núm. 1, pp. 1-6

2021

  1. Gut microbiota and the quality of oral anticoagulation in vitamin K antagonists users: A review of potential implications

    Journal of Clinical Medicine, Vol. 10, Núm. 4, pp. 1-16

  2. Non-vitamin K Antagonist Oral Anticoagulants and Drug-Food Interactions: Implications for Clinical Practice and Potential Role of Probiotics and Prebiotics

    Frontiers in Cardiovascular Medicine

  3. Outcomes in VKA-treated patients with atrial fibrillation and chronic kidney disease: Clinical trials vs ‘real-world’

    International Journal of Clinical Practice, Vol. 75, Núm. 4

  4. Prediction of residual stroke risk in anticoagulated patients with atrial fibrillation: mCARS

    Journal of Clinical Medicine, Vol. 10, Núm. 15

  5. Relationship between multimorbidity and outcomes in atrial fibrillation

    Experimental Gerontology, Vol. 153

  6. Validating scores predicting atrial fibrillation recurrence post catheter ablation in patients with concurrent atrial fibrillation and pulmonary diseases

    Annals of palliative medicine, Vol. 10, Núm. 4, pp. 4299-4307

2020

  1. A nurse-led atrial fibrillation clinic: Impact on anticoagulation therapy and clinical outcomes

    International Journal of Clinical Practice, Vol. 74, Núm. 12